The Kazakh government has approved a major investment agreement aimed at boosting domestic pharmaceutical production and strengthening the country’s drug security.

The deal, signed by Prime Minister Olzhas Bektenov, formalizes cooperation between the Healthcare Ministry and Khimpharm company. The agreement launches a large-scale expansion of pharmaceutical manufacturing in Shymkent as part of the Polpharma Santo investment project, The Caspian Post reports via Kazakh media.

The initiative is designed to increase the share of locally produced medicines, enhance pharmaceutical safety, and attract new investments into the sector. The project will create 300 new jobs and bring in 39.5 billion tenge ($79.539 million) in private investment, including funding for scientific research.

The first phase of the new production facility is scheduled for completion by the end of 2029. Once operational, the plant will manufacture 38 types of medicines used to treat widespread conditions such as cancer, cardiovascular diseases, infectious illnesses, and tuberculosis. Production will comply with international quality standards.

Officials say the project will strengthen Kazakhstan’s pharmaceutical independence, expand export potential, and build a sustainable technological base for the industry.

Overall, six investment agreements worth 316.3 billion tenge ($636.919 million) have been signed in Kazakhstan’s pharmaceutical sector, reflecting steady growth and rising investor confidence. Earlier, authorities in Astana announced plans to build 11 new medical facilities over the next four years, further signaling expansion in the country’s healthcare infrastructure.